904 related articles for article (PubMed ID: 27272189)
21. Section 14. Combination of entecavir plus low-dose on-demand hepatitis B immunoglobulin is effective with very low hepatitis B recurrence after liver transplantation.
Hu TH; Chen CL; Lin CC; Wang CC; Chiu KW; Yong CC; Liu YW; Eng HL
Transplantation; 2014 Apr; 97 Suppl 8():S53-9. PubMed ID: 24849836
[TBL] [Abstract][Full Text] [Related]
22. Entecavir and other nucleos(t)ide analogs prophylaxis in hepatitis B virus-related liver transplantation: long-term efficacy and safety.
Darweesh SK; Gad AA; Akroof K; ElLatif ZA
Eur J Gastroenterol Hepatol; 2019 May; 31(5):607-612. PubMed ID: 30724767
[TBL] [Abstract][Full Text] [Related]
23. HBsAg level at time of liver transplantation determines HBsAg decrease and anti-HBs increase and affects HBV DNA decrease during early immunoglobulin administration.
Rosenau J; Kreutz T; Kujawa M; Bahr MJ; Rifai K; Hooman N; Finger A; Michel G; Nashan B; Kuse ER; Klempnauer J; Tillmann HL; Manns MP
J Hepatol; 2007 Apr; 46(4):635-44. PubMed ID: 17316869
[TBL] [Abstract][Full Text] [Related]
24. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
[TBL] [Abstract][Full Text] [Related]
25. Low-dose anti-hepatitis B immunoglobulin regimen as prophylaxis for hepatitis B recurrence after liver transplantation.
Lee WC; Chou HS; Wu TH; Cheng CH; Lee CF; Wang YC; Wu TJ; Chan KM
Transpl Infect Dis; 2019 Dec; 21(6):e13190. PubMed ID: 31587427
[TBL] [Abstract][Full Text] [Related]
26. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective.
Wesdorp DJ; Knoester M; Braat AE; Coenraad MJ; Vossen AC; Claas EC; van Hoek B
J Clin Virol; 2013 Sep; 58(1):67-73. PubMed ID: 23880162
[TBL] [Abstract][Full Text] [Related]
27. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation.
Gane EJ; Angus PW; Strasser S; Crawford DH; Ring J; Jeffrey GP; McCaughan GW;
Gastroenterology; 2007 Mar; 132(3):931-7. PubMed ID: 17383422
[TBL] [Abstract][Full Text] [Related]
28. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation.
Ueda Y; Marusawa H; Egawa H; Okamoto S; Ogura Y; Oike F; Nishijima N; Takada Y; Uemoto S; Chiba T
Antivir Ther; 2011; 16(4):479-87. PubMed ID: 21685535
[TBL] [Abstract][Full Text] [Related]
29. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
[TBL] [Abstract][Full Text] [Related]
30. The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients.
Urabe A; Imamura M; Tsuge M; Kan H; Fujino H; Fukuhara T; Masaki K; Kobayashi T; Ono A; Nakahara T; Kawaoka T; Hiramatsu A; Kawakami Y; Aikata H; Hayes CN; Maki N; Ohdan H; Chayama K
J Gastroenterol; 2017 Mar; 52(3):366-375. PubMed ID: 27422771
[TBL] [Abstract][Full Text] [Related]
31. Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.
De Simone P; Romagnoli R; Tandoi F; Carrai P; Ercolani G; Peri E; Zamboni F; Mameli L; Di Benedetto F; Cillo U; De Carlis L; Lauterio A; Lupo L; Tisone G; Prieto M; Loinaz C; Mas A; Suddle A; Mutimer D; Roche B; Wartenberg-Demand A; Niemann G; Böhm H; Samuel D
Transplantation; 2016 Jul; 100(7):1507-12. PubMed ID: 27023394
[TBL] [Abstract][Full Text] [Related]
32. A Very Short Course of HBIg+NA Followed by Entecavir or Tenofovir Monotherapy Prevents HBV Recurrence in Low-Risk Liver Transplant Recipients.
Manini MA; Bruce M; Whitehouse G; Mazzarelli C; Considine A; Agarwal K; Suddle A; Fagiuoli S; Heaton N; Heneghan M
Transplant Proc; 2021; 53(1):207-214. PubMed ID: 32605776
[TBL] [Abstract][Full Text] [Related]
33. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation.
Sánchez-Fueyo A; Rimola A; Grande L; Costa J; Mas A; Navasa M; Cirera I; Sánchez-Tapias JM; Rodés J
Hepatology; 2000 Feb; 31(2):496-501. PubMed ID: 10655276
[TBL] [Abstract][Full Text] [Related]
34. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.
Naoumov NV; Lopes AR; Burra P; Caccamo L; Iemmolo RM; de Man RA; Bassendine M; O'Grady JG; Portmann BC; Anschuetz G; Barrett CA; Williams R; Atkins M
J Hepatol; 2001 Jun; 34(6):888-94. PubMed ID: 11451173
[TBL] [Abstract][Full Text] [Related]
36. Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal.
Manini MA; Whitehouse G; Bruce M; Passerini M; Lim TY; Carey I; Considine A; Lampertico P; Suddle A; Heaton N; Heneghan M; Agarwal K
Dig Liver Dis; 2018 Sep; 50(9):944-953. PubMed ID: 29735294
[TBL] [Abstract][Full Text] [Related]
37. Anti-virus prophylaxis withdrawal may be feasible in liver transplant recipients whose serum HBeAg and HBV DNA are negative.
Geng L; Lin BY; Shen T; Guo H; Ye YF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2016 Jun; 15(3):316-8. PubMed ID: 27298109
[TBL] [Abstract][Full Text] [Related]
38. Entecavir Combined With Short-term Hepatitis B Immunoglobulin in Preventing Hepatitis B Virus Recurrence in Liver Transplant Recipients.
Zheng H; Zhu Z; Wang N; Qin J; Guo Y; Xu Z; Li X; Qi C; Yuan X; Wu W; Wang J; Liu L; Nashan B
Transplant Proc; 2023 Mar; 55(2):408-412. PubMed ID: 36907782
[TBL] [Abstract][Full Text] [Related]
39. Deep sequencing shows low-level oncogenic hepatitis B virus variants persists post-liver transplant despite potent anti-HBV prophylaxis.
Lau KCK; Osiowy C; Giles E; Lusina B; van Marle G; Burak KW; Coffin CS
J Viral Hepat; 2018 Jun; 25(6):724-732. PubMed ID: 29316067
[TBL] [Abstract][Full Text] [Related]
40. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers.
Lee S; Kim JM; Choi GS; Park JB; Kwon CH; Choe YH; Joh JW; Lee SK
Liver Transpl; 2016 Feb; 22(2):247-51. PubMed ID: 26600319
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
